Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,100 shares, an increase of 24.2% from the September 30th total of 3,300 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average trading volume of 9,600 shares, the days-to-cover ratio is currently 0.4 days.
Wall Street Analyst Weigh In
Separately, Chardan Capital reaffirmed a “buy” rating and issued a $3.00 target price on shares of Forte Biosciences in a research note on Monday, August 19th.
Read Our Latest Stock Analysis on Forte Biosciences
Forte Biosciences Stock Performance
Forte Biosciences (NASDAQ:FBRX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.11). On average, equities research analysts predict that Forte Biosciences will post -22.5 EPS for the current fiscal year.
Forte Biosciences Company Profile
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Further Reading
- Five stocks we like better than Forte Biosciences
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- High Flyers: 3 Natural Gas Stocks for March 2022
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.